Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | SVP, Chief Scientific Officer | November 13, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date November 13, 2019 · Filed November 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.28 · Expires 2029-04-15 | Direct | 0 |
Reported balance
After 2019-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-13 · Disposition to issuer · Disposed 153,846 · Balance 0 F1: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2029-04-15 | Direct | 153,846 |
Reported balance
After 2019-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-13 · Grant · Acquired 153,846 · Balance 153,846 F1: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2019 Filed Nov 14, 2019 22:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 153,846 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0001723128-19-000129 · wf-form4_157377039293557.xml · derivative · entry 2 Bhadauria Pradeep · CIK 0001774812 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,846 Underlying: Class A Common Stock · 153,846 shares Expires 2029-04-15 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Disposition to issuerStock Option · Derivative | 153,846 | Not disclosed Strike: $13.28 | Not disclosed |
DisclosureSEC source: 0001723128-19-000129 · wf-form4_157377039293557.xml · derivative · entry 1 Bhadauria Pradeep · CIK 0001774812 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 153,846 shares Expires 2029-04-15 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 15, 2019, and will vest in four equal annual installments beginning on April 15, 2020. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 01:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 30,000 | $2.41 | $72,300.00 |
DisclosureSEC source: 0001723128-19-000118 · wf-form4_156626296989842.xml · nonDerivative · entry 1 Bhadauria Pradeep · CIK 0001774812 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.40 per share to $2.43 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:59 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 7,000 | $8.48 | $59,360.00 |
DisclosureSEC source: 0001723128-19-000097 · wf-form4_155804037951157.xml · nonDerivative · entry 1 Bhadauria Pradeep · CIK 0001774812 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $8.30 per share to $8.55 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.